Sebastian Böettcher

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo et al. · New England Journal of Medicine · 2019 · 852 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Michael Hallek, Guenter Fingerle-Rowson, Anna Maria Fink et al. · Blood · 2008 · 134 citations

Medicine, Oncology, Pharmacotherapy +14

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.

Michael Hallek, Guenter Fingerle-Rowson, Anna‐Maria Fink et al. · Blood · 2009 · 90 citations

Medicine, Oncology, Pharmacotherapy +12

Evaluation of ZAP‐70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process

Rémi Letestu, Andy C. Rawstron, Paolo Ghia et al. · Cytometry Part B Clinical Cytometry · 2006 · 85 citations · Full text

Medicine, Hematology, Immunology +13

Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, Paula Cramer, Stephan Stilgenbauer et al. · Blood · 2009 · 82 citations

Medicine, Oncology, Pharmacotherapy +5